Surrogate study endpoints in the era of cancer immunotherapy.
作者信息
Hamada Tsuyoshi, Kosumi Keisuke, Nakai Yousuke, Koike Kazuhiko
机构信息
Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
出版信息
Ann Transl Med. 2018 Nov;6(Suppl 1):S27. doi: 10.21037/atm.2018.09.31.
Abstract
摘要
相似文献
1
Surrogate study endpoints in the era of cancer immunotherapy.癌症免疫治疗时代的替代研究终点
Ann Transl Med. 2018 Nov;6(Suppl 1):S27. doi: 10.21037/atm.2018.09.31.
2
Intermediate markers as surrogate endpoints in cancer research.癌症研究中作为替代终点的中间标志物。
Hematol Oncol Clin North Am. 2000 Aug;14(4):887-905. doi: 10.1016/s0889-8588(05)70317-8.
3
Surrogate clinical endpoints to predict overall survival in non-small cell lung cancer trials-are we in a new era?非小细胞肺癌临床试验中替代临床终点预测总生存期：我们是否进入了一个新时代？
Transl Lung Cancer Res. 2015 Dec;4(6):804-8. doi: 10.3978/j.issn.2218-6751.2015.05.03.
4
Surrogate endpoints for overall survival in advanced colorectal cancer: a clinician's perspective.晚期结直肠癌总生存替代终点：临床医生视角
Stat Methods Med Res. 2008 Oct;17(5):519-27. doi: 10.1177/0962280207081865. Epub 2008 Feb 19.
5
Combining tumour response and progression free survival as surrogate endpoints for overall survival in advanced colorectal cancer.将肿瘤反应和无进展生存期联合作为晚期结直肠癌总生存期的替代终点。
Cancer Epidemiol. 2020 Feb;64:101665. doi: 10.1016/j.canep.2019.101665. Epub 2020 Jan 5.
6
Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists.消化系统肿瘤临床试验中总生存的替代终点：哪些候选物？临床医生和方法学家问卷调查。
BMC Cancer. 2010 Jun 10;10:277. doi: 10.1186/1471-2407-10-277.
7
Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review.Meta 分析评估癌症随机试验中总生存的替代终点：批判性评价。
Crit Rev Oncol Hematol. 2018 Mar;123:21-41. doi: 10.1016/j.critrevonc.2017.11.014. Epub 2017 Nov 23.
8
Significance of emerging clinical oncology endpoints in support of overall survival.新兴临床肿瘤学终点在支持总生存期方面的意义。
Indian J Cancer. 2022 Mar;59(Supplement):S106-S118. doi: 10.4103/ijc.IJC_1417_20.
9
A two-stage procedure for survival studies with surrogate endpoints.
Biometrics. 1995 Sep;51(3):969-76.
10
The current role and limitations of surrogate endpoints in advanced prostate cancer.晚期前列腺癌中替代终点的作用和局限性。
Urol Oncol. 2014 Jan;32(1):28.e1-9. doi: 10.1016/j.urolonc.2012.10.001. Epub 2013 Feb 20.
引用本文的文献
1
THOR: a TMB heterogeneity-adaptive optimization model predicts immunotherapy response using clonal genomic features in group-structured data.THOR：一种肿瘤突变负荷异质性自适应优化模型，利用群体结构数据中的克隆基因组特征预测免疫治疗反应。
Brief Bioinform. 2024 Nov 22;26(1). doi: 10.1093/bib/bbae648.
2
Tislelizumab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of advanced non-small cell lung cancer: systematic review and indirect comparison of randomized trials.替雷利珠单抗联合化疗与帕博利珠单抗联合化疗用于晚期非小细胞肺癌一线治疗的系统评价和随机试验间接比较
Front Pharmacol. 2023 Jun 20;14:1172969. doi: 10.3389/fphar.2023.1172969. eCollection 2023.
3
NMR-Based Metabolomics to Evaluate Individual Response to Treatments.基于核磁共振的代谢组学用于评估个体对治疗的反应。
Handb Exp Pharmacol. 2023;277:209-245. doi: 10.1007/164_2022_618.
4
OSPred Tool: A Digital Health Aid for Rapid Predictive Analysis of Correlations Between Early End Points and Overall Survival in Non-Small-Cell Lung Cancer Clinical Trials.OSPred 工具：一种数字健康辅助工具，用于快速预测分析非小细胞肺癌临床试验中早期终点与总生存期之间的相关性。
JCO Clin Cancer Inform. 2022 Mar;6:e2100173. doi: 10.1200/CCI.21.00173.
5
The role of fructose 1,6-bisphosphate-mediated glycolysis/gluconeogenesis genes in cancer prognosis.果糖-1,6-二磷酸介导的糖酵解/糖异生基因在癌症预后中的作用。
Aging (Albany NY). 2022 Apr 11;14(7):3233-3258. doi: 10.18632/aging.204010.
6
Systematic literature review of trials assessing recommended systemic treatments in hepatocellular carcinoma.评估肝细胞癌推荐全身治疗的试验的系统文献综述
Hepat Oncol. 2021 Aug 26;9(1):HEP41. doi: 10.2217/hep-2021-0003. eCollection 2022 Mar.
7
Correlation Between Early Endpoints and Overall Survival in Non-Small-Cell Lung Cancer: A Trial-Level Meta-Analysis.非小细胞肺癌早期终点与总生存期的相关性：一项试验水平的荟萃分析
Front Oncol. 2021 Jul 26;11:672916. doi: 10.3389/fonc.2021.672916. eCollection 2021.
8
Long Noncoding RNAs: New Regulators of Resistance to Systemic Therapies for Gastric Cancer.长链非编码 RNA：胃癌系统治疗耐药的新调控因子。
Biomed Res Int. 2021 Jan 6;2021:8853269. doi: 10.1155/2021/8853269. eCollection 2021.
9
Metabolomics to Assess Response to Immune Checkpoint Inhibitors in Patients with Non-Small-Cell Lung Cancer.代谢组学评估非小细胞肺癌患者对免疫检查点抑制剂的反应
Cancers (Basel). 2020 Nov 30;12(12):3574. doi: 10.3390/cancers12123574.
10
Master protocols in immuno-oncology: do novel drugs deserve novel designs?免疫肿瘤学中的主方案：新型药物是否需要新的设计？
J Immunother Cancer. 2020 Mar;8(1). doi: 10.1136/jitc-2019-000475.
本文引用的文献
1
TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas.基于结直肠癌中肿瘤程序性死亡受体配体1（PD-L1）表达状态和肿瘤浸润淋巴细胞的TIME（肿瘤微环境中的肿瘤免疫）分类
Oncoimmunology. 2018 Mar 19;7(7):e1442999. doi: 10.1080/2162402X.2018.1442999. eCollection 2018.
2
Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis.定义晚期实体瘤免疫检查点抑制剂的 2 期临床试验最合适的主要终点：系统评价和荟萃分析。
JAMA Oncol. 2018 Apr 1;4(4):522-528. doi: 10.1001/jamaoncol.2017.5236.
3
Tumor Mutational Burden and Response Rate to PD-1 Inhibition.肿瘤突变负荷与对PD-1抑制的反应率
N Engl J Med. 2017 Dec 21;377(25):2500-2501. doi: 10.1056/NEJMc1713444.
4
Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer.癌症免疫检查点抑制反应的分子和基因组决定因素。
Annu Rev Med. 2018 Jan 29;69:333-347. doi: 10.1146/annurev-med-060116-022926. Epub 2017 Nov 3.
5
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.纳武利尤单抗治疗转移性DNA错配修复缺陷或微卫星高度不稳定结直肠癌患者（CheckMate 142）：一项开放标签、多中心、2期研究。
Lancet Oncol. 2017 Sep;18(9):1182-1191. doi: 10.1016/S1470-2045(17)30422-9. Epub 2017 Jul 19.
6
Monitoring immune-checkpoint blockade: response evaluation and biomarker development.监测免疫检查点阻断：疗效评估与生物标志物开发
Nat Rev Clin Oncol. 2017 Nov;14(11):655-668. doi: 10.1038/nrclinonc.2017.88. Epub 2017 Jun 27.
7
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.错配修复缺陷可预测实体瘤对程序性死亡受体1（PD-1）阻断疗法的反应。
Science. 2017 Jul 28;357(6349):409-413. doi: 10.1126/science.aan6733. Epub 2017 Jun 8.
8
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.iRECIST：免疫治疗试验中使用的疗效评估标准指南。
Lancet Oncol. 2017 Mar;18(3):e143-e152. doi: 10.1016/S1470-2045(17)30074-8. Epub 2017 Mar 2.
9
Cancer Statistics, 2017.《2017 年癌症统计》
CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5.
10
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.抗 PD-1/PD-L1 治疗的癌症患者中出现的一种新的疾病进展模式：超进展性疾病
Clin Cancer Res. 2017 Apr 15;23(8):1920-1928. doi: 10.1158/1078-0432.CCR-16-1741. Epub 2016 Nov 8.
Zotero 插件